Botulinum neurotoxin (BoNT) treatment in functional movement disorders: long-term follow-up

摘要: We recently reported on a randomised controlled trial (RCT) assessing the effect of botulinum neurotoxin (BoNT) in 48 patients with chronic (>1 year) jerky and tremulous functional movement disorders (FMD).1 The RCT showed an improvement motor symptoms both treatment arms (16/25, 64% BoNT vs 13/23, 57% placebo). proportion improved increased to 81% (35/43) at end open-label phase. Despite symptom improvement, there was no change quality life disability. In present study, our aim assess long-term outcome this study population. ### Population design Included were aged between 18 80 years disabling or minimum duration 1 year.1 ### Procedures All who participated approached via letter email. Patients interviewed by telephone (FL) self-assessment questionnaires sent patients’ homes. compared measures current baseline (start RCT) phase. ### Outcome measures A selection previously used used.1 Self-rated (Clinical Global ImpressionImprovement Scale (CGI-I)) severity Impression-Severity-Scale (CGI-S)), disease burden (VAS scale), physical functioning (Short-Form-36 (Sf-36)), depressive (Beck Depression Inventory (BDI)) anxiety Anxiety (BAI)) evaluated. questioned about their employment status, (or other) new neurologic (FNSs). ### Statistical analysis Demographic characteristics analysed using descriptive statistics. categorised based CGI-I follow-up into three groups. first group, ‘improved’ group (group 1), second …